Beschreibung
This book elaborates on current practices and policies relating to the research, development, dissemination and application of therapies aimed at improving degenerative ageing processes and extending healthy, productive longevity. It explores the intersection of longevity science, technology and society, and addresses issues such as R&D and educational policies, governance, regulation and the accessibility of emerging therapies. It examines the practical implementation of policies for longevity therapy research, including the factors that hinder or encourage beneficial development. Key topics include the definition and evaluation of clinical benefits, regulatory frameworks and methodological issues in geroscience research. The book also considers the practical benefits of longevity studies and emerging therapies, with a focus on safety, efficacy, standardisation, and universal distribution. Written by world-leading experts, this book makes a valuable contribution to the analysis of methodological and policy challenges, and the devising of biomedical and societal solutions to improve healthy longevity for the population.
Autorenporträt
Ilia Stambler, PhD, is the Chief Science Officer and Chairman of Vetek (Seniority) Association - the Movement for Longevity and Quality of Life, Israel, and Chairman of International Longevity Alliance (ILA). He is a fellow at the Department of Science, Technology and Society, Bar Ilan University, Israel. His research focuses on the historical and social implications of aging and longevity research, including ethical, policy, and regulatory aspects. Dr. Stambler is actively involved in advocacy for aging and longevity research and holds leadership roles in multiple organizations for healthy longevity research and advocacy. He has authored several books and over 80 academic papers.
Herstellerkennzeichnung:
Springer Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg
DE
E-Mail: juergen.hartmann@springer.com
